3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
23
Glioblastoma
13
Lymphoma, Mantle-Cell
10
Endometrial Neoplasms
10
Prostatic Neoplasms
9
Neoplasms
9
Breast Neoplasms
9
Brain Neoplasms
9
Neoplasm Metastasis
8
Kidney Neoplasms
8
Gliosarcoma
8
Melanoma
7
Sarcoma
6
Lymphoma, Non-Hodgkin
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Ovarian Neoplasms
5
Oligodendroglioma
5
Multiple Myeloma
5
Lymphoma, Follicular
5
Lymphoma
5
Glioma
5
Astrocytoma
5
Waldenstrom Macroglobulinemia
4
Uterine Cervical Neoplasms
4
Lymphoma, B-Cell, Marginal Zone
4
Fallopian Tube Neoplasms
4
Central Nervous System Neoplasms
4
Unspecified Adult Solid Tumor, Protocol Specific
3
Rhabdomyosarcoma
3
Osteosarcoma
3
Interventions
padeliporfin
4
motexafin gadolinium
2
Sunitinib
2
Radiotherapy
2
Paclitaxel
2
Genetic Testing
2
Carboplatin
2
vinflunine
1
temsirolimus
1
sipuleucel-T
1
niraparib
1
luprolide acetate gel depot
1
apalutamide
1
Tinzaparin
1
Therapeutics
1
Taste
1
Surveys and Questionnaires
1
Specimen Handling
1
Sildenafil Citrate
1
Remote Patient Monitoring
1
Radiation Dose Hypofractionation
1
Pemetrexed
1
Ocoxin
1
Neoadjuvant Therapy
1
Leuprolide
1
Immunotherapy
1
Imatinib Mesylate
1
Imagery, Psychotherapy
1
Genetic Counseling
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Urogenital Neoplasms
×
temsirolimus
×
Clear all
NCT00631371
2016-04-27
INTORACT
Pfizer
Phase 3
Completed
791 enrolled
11 charts